<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" dtd-version="1.3" xml:lang="EN" article-type="rapid-communication"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">ACS Med Chem Lett</journal-id><journal-id journal-id-type="iso-abbrev">ACS Med Chem Lett</journal-id><journal-id journal-id-type="publisher-id">ml</journal-id><journal-id journal-id-type="coden">amclct</journal-id><journal-title-group><journal-title>ACS Medicinal Chemistry Letters</journal-title></journal-title-group><issn pub-type="epub">1948-5875</issn><publisher><publisher-name>American Chemical Society</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC10726441</article-id><article-id pub-id-type="doi">10.1021/acsmedchemlett.3c00326</article-id><article-categories><subj-group><subject>Letter</subject></subj-group></article-categories><title-group><article-title>Discovery
of Tumor-Targeted 6-Methyl Substituted
Pemetrexed and Related Antifolates with Selective Loss of RFC Transport</article-title></title-group><contrib-group><contrib contrib-type="author" id="ath1"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3073-8060</contrib-id><name><surname>Kaku</surname><given-names>Krishna</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath2"><name><surname>Ravindra</surname><given-names>Manasa P.</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath3"><name><surname>Tong</surname><given-names>Nian</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath4"><name><surname>Choudhary</surname><given-names>Shruti</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath5"><name><surname>Li</surname><given-names>Xinxin</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath6"><name><surname>Yu</surname><given-names>Jianming</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath7"><name><surname>Karim</surname><given-names>Mohammad</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath8"><name><surname>Brzezinski</surname><given-names>Madelyn</given-names></name><xref rid="aff3" ref-type="aff">&#x000a7;</xref></contrib><contrib contrib-type="author" id="ath9"><name><surname>O&#x02019;Connor</surname><given-names>Carrie</given-names></name><xref rid="aff3" ref-type="aff">&#x000a7;</xref></contrib><contrib contrib-type="author" id="ath10"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5631-5202</contrib-id><name><surname>Hou</surname><given-names>Zhanjun</given-names></name><xref rid="aff2" ref-type="aff">&#x02021;</xref><xref rid="aff3" ref-type="aff">&#x000a7;</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath11"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6860-8133</contrib-id><name><surname>Matherly</surname><given-names>Larry H.</given-names></name><xref rid="cor1" ref-type="other">*</xref><xref rid="aff2" ref-type="aff">&#x02021;</xref><xref rid="aff3" ref-type="aff">&#x000a7;</xref><xref rid="aff4" ref-type="aff">&#x02225;</xref><xref rid="notes2" ref-type="notes">&#x022a5;</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath12"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5513-7616</contrib-id><name><surname>Gangjee</surname><given-names>Aleem</given-names></name><xref rid="cor2" ref-type="other">*</xref><xref rid="aff1" ref-type="aff">&#x02020;</xref><xref rid="notes2" ref-type="notes">&#x022a5;</xref></contrib><aff id="aff1"><label>&#x02020;</label>Division
of Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, <institution>Duquesne University</institution>, 600 Forbes Avenue, Pittsburgh, Pennsylvania 15282, <country>United States</country></aff><aff id="aff2"><label>&#x02021;</label>Molecular
Therapeutics Program, <institution>Barbara Ann Karmanos
Cancer Institute</institution>, 4100 John R, Detroit, Michigan 48201, <country>United States</country></aff><aff id="aff3"><label>&#x000a7;</label>Department
of Oncology, <institution>Wayne State University School
of Medicine</institution>, Detroit, Michigan 48201, <country>United States</country></aff><aff id="aff4"><label>&#x02225;</label>Department
of Pharmacology, <institution>Wayne State University
School of Medicine</institution>, Detroit, Michigan 48201, <country>United States</country></aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Email: <email>matherly@karmanos.org</email>. Phone: <phone>313-578-4280</phone>.</corresp><corresp id="cor2"><label>*</label><email>gangjee@duq.edu</email>.</corresp></author-notes><pub-date pub-type="epub"><day>15</day><month>11</month><year>2023</year></pub-date><pub-date pub-type="collection"><day>14</day><month>12</month><year>2023</year></pub-date><pub-date pub-type="pmc-release"><day>15</day><month>11</month><year>2023</year></pub-date><volume>14</volume><issue>12</issue><fpage>1682</fpage><lpage>1691</lpage><history><date date-type="received"><day>26</day><month>07</month><year>2023</year></date><date date-type="accepted"><day>10</day><month>11</month><year>2023</year></date><date date-type="rev-recd"><day>09</day><month>11</month><year>2023</year></date></history><permissions><copyright-statement>&#x000a9; 2023 The Authors. Published by American Chemical Society</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>The Authors</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p content-type="toc-graphic"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ml3c00326_0010" id="ab-tgr1"/></p><p>Pemetrexed and related 5-substituted pyrrolo[2,3-<italic>d</italic>]pyrimidine antifolates are substrates for the ubiquitously
expressed
reduced folate carrier (RFC), and the proton-coupled folate transporter
(PCFT) and folate receptors (FRs) which are more tumor-selective.
A long-standing goal has been to discover tumor-targeted therapeutics
that draw from one-carbon metabolic vulnerabilities of cancer cells
and are selective for transport by FRs and PCFT over RFC. We discovered
that a methyl group at the 6-position of the pyrrole ring in the bicyclic
scaffold of 5-substituted 2-amino-4-oxo-pyrrolo[2,3-<italic>d</italic>]pyrimidine antifolates <bold>1</bold>&#x02013;<bold>4</bold> (including
pemetrexed) abolished transport by RFC with modest impacts on FRs
or PCFT. From molecular modeling, loss of RFC transport involves steric
repulsion in the scaffold binding site due to the 6-methyl moiety.
6-Methyl substitution preserved antiproliferative activities toward
human tumor cells (KB, IGROV3) with selectivity over IOSE 7576 normal
ovary cells and inhibition of <italic>de novo</italic> purine biosynthesis.
Thus, adding a 6-methyl moiety to 5-substituted pyrrolo[2,3-<italic>d</italic>]pyrimidine antifolates affords tumor transport selectivity
while preserving antitumor efficacy.</p></abstract><kwd-group><kwd>Antifolate</kwd><kwd>Folate receptor</kwd><kwd>Pemetrexed</kwd><kwd>Proton-coupled folate transporter</kwd><kwd>Reduced folate carrier</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution>Division of Cancer Prevention, National Cancer Institute</institution><institution-id institution-id-type="doi">10.13039/100007316</institution-id></institution-wrap></funding-source><award-id>R01 CA250469</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution>Eunice and Milton Ring Endowed Chair for Cancer Research</institution><institution-id institution-id-type="doi">NA</institution-id></institution-wrap></funding-source><award-id>NA</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution>Duquesne University</institution><institution-id institution-id-type="doi">10.13039/100009854</institution-id></institution-wrap></funding-source><award-id>NA</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution>Division of Cancer Prevention, National Cancer Institute</institution><institution-id institution-id-type="doi">10.13039/100007316</institution-id></institution-wrap></funding-source><award-id>R01 CA53535</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>ml3c00326</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>ml3c00326</meta-value></custom-meta><custom-meta><meta-name>ccc-price</meta-name><meta-value/></custom-meta></custom-meta-group></article-meta></front><body><p>One-carbon (C1) metabolism offers
an important therapeutic target for many cancers, reflecting its role
in the biosynthesis of purines, thymidylate, serine, and methionine,
and in supporting biological methylation reactions from S-adenosylmethione.<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> Chemotherapy with antifolates has been a cornerstone
of cancer therapy for over 60 years.<sup><xref ref-type="bibr" rid="ref2">2</xref></sup> Clinically
used antifolates include methotrexate (MTX), pemetrexed (PMX), pralatrexate
(PTX), and raltitrexed (RTX) (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>). While antifolates serve important roles in the therapeutic
armamentarium for cancer, they manifest clinical challenges, most
notably dose-limiting toxicities and emergence of drug resistance.<sup><xref ref-type="bibr" rid="ref2">2</xref></sup></p><fig id="fig1" position="float"><label>Figure 1</label><caption><p>Clinically used antifolates.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ml3c00326_0001" id="gr1" position="float"/></fig><p>Membrane transport of antifolates is integral to
their therapeutic
efficacy in treating a variety of malignancies and nonmalignant conditions.<sup><xref ref-type="bibr" rid="ref2">2</xref>,<xref ref-type="bibr" rid="ref3">3</xref></sup> Pharmacologically important folate transporters include the reduced
folate carrier (RFC) (SLC19A1), the proton-coupled folate transporter
(PCFT) (SLC46A1), and the high-affinity folate receptor (FR) &#x003b1;
and FR&#x003b2;.<sup><xref ref-type="bibr" rid="ref4">4</xref>&#x02212;<xref ref-type="bibr" rid="ref8">8</xref></sup> These systems mediate cellular accumulations of folate cofactors
and classic antifolates; however, they have different substrate specificities
and mechanisms.<sup><xref ref-type="bibr" rid="ref3">3</xref>,<xref ref-type="bibr" rid="ref5">5</xref>,<xref ref-type="bibr" rid="ref7">7</xref>&#x02212;<xref ref-type="bibr" rid="ref9">9</xref></sup> Both RFC and PCFT are facilitative transporters;
RFC is a folate-organic anion antiporter,<sup><xref ref-type="bibr" rid="ref5">5</xref></sup> and PCFT is a folate-proton symporter.<sup><xref ref-type="bibr" rid="ref7">7</xref></sup> FRs are glycosyl phosphatidylinositol-modified proteins that mediate
cellular uptake of (anti)folates by receptor-mediated endocytosis.<sup><xref ref-type="bibr" rid="ref4">4</xref>,<xref ref-type="bibr" rid="ref10">10</xref></sup></p><p>RFC is ubiquitously expressed and is the major tissue transporter
of folates.<sup><xref ref-type="bibr" rid="ref5">5</xref></sup> Dose-limiting toxicities of
classic antifolates are partially due to their membrane transport
by RFC in both normal tissues and tumors.<sup><xref ref-type="bibr" rid="ref5">5</xref></sup> In addition, loss of transport in tumors due to decreased expression
or mutation of RFC results in insufficient levels of intracellular
antifolates to inhibit metabolic targets and sustain polyglutamate
synthesis.<sup><xref ref-type="bibr" rid="ref5">5</xref>,<xref ref-type="bibr" rid="ref11">11</xref></sup></p><p>PCFT is the major mechanism for intestinal
folate uptake.<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> Although PCFT is expressed
in a select number
of other tissues including the choroid plexus, kidney, liver, and
spleen,<sup><xref ref-type="bibr" rid="ref13">13</xref>,<xref ref-type="bibr" rid="ref14">14</xref></sup> PCFT is not a major tissue transporter of
folates. Further, transport by PCFT is optimal at acidic pHs not commonly
associated with most tissues,<sup><xref ref-type="bibr" rid="ref13">13</xref>,<xref ref-type="bibr" rid="ref15">15</xref></sup> and the modest level
of PCFT transport that occurs at neutral pH is suppressed by bicarbonate.<sup><xref ref-type="bibr" rid="ref16">16</xref></sup> Notably, PCFT is expressed in solid tumors including
malignant pleural mesothelioma,<sup><xref ref-type="bibr" rid="ref17">17</xref></sup> pancreatic
adenocarcinoma,<sup><xref ref-type="bibr" rid="ref18">18</xref></sup> nonsmall cell lung cancer,<sup><xref ref-type="bibr" rid="ref19">19</xref></sup> and epithelial ovarian cancer<sup><xref ref-type="bibr" rid="ref20">20</xref></sup> and is highly active in the acidic tumor microenvironment.<sup><xref ref-type="bibr" rid="ref6">6</xref>,<xref ref-type="bibr" rid="ref13">13</xref></sup></p><p>FR&#x003b1; is expressed in normal epithelial tissues such as
kidney,
lung, choroid plexus, and placenta and in several tumors including
ovarian cancer, nonsmall cell lung cancer, triple negative breast
cancer, and kidney, endometrial, and colorectal cancers.<sup><xref ref-type="bibr" rid="ref4">4</xref>,<xref ref-type="bibr" rid="ref9">9</xref>,<xref ref-type="bibr" rid="ref21">21</xref></sup> However, only FR&#x003b1; in tumors
exhibits the basolateral exposure required for access to the circulation.<sup><xref ref-type="bibr" rid="ref4">4</xref></sup> FR&#x003b2; is expressed in placenta, mature neutrophils,
and activated monocytes and macrophages, along with acute myeloid
leukemia (AML) blasts.<sup><xref ref-type="bibr" rid="ref4">4</xref>,<xref ref-type="bibr" rid="ref9">9</xref></sup></p><p>PMX (<bold>1</bold>) is
a 5-substituted pyrrolo[2,3-<italic>d</italic>]pyrimidine benzoyl
antifolate with a 2-carbon bridge (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>). PMX primarily inhibits thymidylate
synthase (TS) with secondary inhibition at glycinamide ribonucleotide
formyltransferase (GARFTase) and 5-aminoimidazole-4-carboxamide (AICA)
ribonucleotide formyl transferase (AICARFTase) in <italic>de novo</italic> purine biosynthesis.<sup><xref ref-type="bibr" rid="ref22">22</xref></sup> The 5-substituted
pyrrolo[2,3-<italic>d</italic>]pyrimidine benozyl compound <bold>2</bold> (3-carbon bridge) and the analogous pyrrolo[2,3-<italic>d</italic>]pyrimidine thienoyl compound <bold>3</bold> (2-carbon bridge) (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>) were reported to
inhibit GARFTase and AICARFTase.<sup><xref ref-type="bibr" rid="ref23">23</xref>,<xref ref-type="bibr" rid="ref24">24</xref></sup> While these
compounds would presumably circumvent resistance due to alterations
in TS, the 5-substituted pyrrolo[2,3-<italic>d</italic>]pyrimidine
compounds including PMX all exhibit promiscuous transport in that
they are substrates for RFC as well as for PCFT and FRs.<sup><xref ref-type="bibr" rid="ref23">23</xref>,<xref ref-type="bibr" rid="ref24">24</xref></sup></p><fig id="fig2" position="float"><label>Figure 2</label><caption><p>6-Unsubstituted
lead compounds (Series I) and the corresponding
6-methyl analogues (Series II).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ml3c00326_0002" id="gr2" position="float"/></fig><p>Our long-standing goal has been to discover potent
folate-based,
tumor-targeted agents that draw from unique C1 metabolic vulnerabilities
of cancer cells and are selective for membrane transport by FRs and
PCFT over RFC.<sup><xref ref-type="bibr" rid="ref13">13</xref>,<xref ref-type="bibr" rid="ref19">19</xref>,<xref ref-type="bibr" rid="ref25">25</xref>&#x02212;<xref ref-type="bibr" rid="ref31">31</xref></sup> We envisage that cytotoxic C1 inhibitors that are selectively transported
by PCFT or FRs with limited transport by RFC would be far less toxic
to normal tissues and would also circumvent resistance due to loss
of RFC.</p><p>We reasoned that if a simple structural modification
could be introduced
into targeted antifolates to abolish RFC transport, while preserving
uptake by FRs and/or PCFT along with intracellular target engagement,
a more effective agent would be realized. One such structural modification
involves adding a 6-methyl group to the 5-subsituted pyrrolo[2,3-<italic>d</italic>]pyrimidine scaffold. We hypothesized that a strategically
placed methyl moiety could sterically hinder drug attachment and net
transport by RFC. As long as the net impact was greater toward RFC
than on either PCFT or FRs, this would result in a more tumor-selective
analogue than the corresponding nonmethylated compound. In addition
to a potential impact on substrate binding to RFC, 6-methyl substitution
also effects conformational restriction on the flexibility of the
5-substituted pyrrolo[2,3-<italic>d</italic>]pyrimidine compounds;
this could further enhance selectivity for transport by PCFT and FRs
over RFC as well as target engagement.</p><p>In this report, we extend
our systematic structure&#x02013;activity
relationship (SAR) studies of pyrrolo[2,3-<italic>d</italic>]pyrimidine
antifolates related to PMX (<bold>1</bold>) by introducing a methyl
group at the unsubstituted 6-position of the pyrrole ring in the bicyclic
scaffolds of 5-substituted pyrrolo[2,3-<italic>d</italic>]pyrimidine
antifolates <bold>1</bold>&#x02013;<bold>4</bold>, generating <bold>5</bold>&#x02013;<bold>8</bold>, respectively (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>). Compound <bold>4</bold>, the fluorinated
analogue of PMX (<bold>1</bold>) and compound <bold>5</bold>, the
6-methyl analogue of PMX (<bold>1</bold>), were published previously;<sup><xref ref-type="bibr" rid="ref32">32</xref>,<xref ref-type="bibr" rid="ref33">33</xref></sup> however, there is no report in the literature regarding their transport
properties.</p><p>Given our goal to test the impact of 6-methyl substitutions
on
5-substituted pyrrolo[2,3-<italic>d</italic>]pyrimidine antifolates <bold>1</bold>&#x02013;<bold>4</bold> on cellular uptake by the pharmacologically
important folate transporters RFC, PCFT, and FRs, it was important
to model the proposed 6-methyl-substituted analogues compared to the
corresponding des-methyl compounds in the known structures for PCFT
(PDB: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="PDB" xlink:href="7BC7">7BC7</ext-link>),<sup><xref ref-type="bibr" rid="ref21">21</xref>,<xref ref-type="bibr" rid="ref34">34</xref></sup> FR&#x003b1; (PDB: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="PDB" xlink:href="5IZQ">5IZQ</ext-link>),<sup><xref ref-type="bibr" rid="ref35">35</xref></sup> FR&#x003b2; (PDB: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="PDB" xlink:href="4KN2">4KN2</ext-link>),<sup><xref ref-type="bibr" rid="ref36">36</xref></sup> and RFC (PDB: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="PDB" xlink:href="8GOF">8GOF</ext-link>).<sup><xref ref-type="bibr" rid="ref37">37</xref></sup> PMX (<bold>1</bold>) and its 6-methyl analogue (<bold>5</bold>) were selected as representative
of the four pairs of des-methyl (<bold>1</bold>&#x02013;<bold>4</bold>) and 6-methyl compounds (<bold>5</bold>&#x02013;<bold>8</bold>) (<bold>Series I and II</bold>, respectively; <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>) for the computational study.</p><p>In <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>, compounds <bold>1</bold> (green) and <bold>5</bold> (purple) and the residues within
5 to 6 &#x000c5; of the C6 position are shown as space-filled models.
The folate binding sites of PCFT (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>a,b), FR&#x003b1; (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>c,d), and FR&#x003b2; (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>e,f) can all accommodate a 6-methyl group,
without any steric hindrance. However, in the binding site for RFC
(<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>g,h), the
6-methyl group of <bold>5</bold> (<bold>panel h</bold>) causes a serious
steric clash with Tyr126, while breaking the edge-to-face &#x003c0;
interaction of the pyrrole ring with Tyr126. Thus, the 6-methyl moiety
of compound <bold>5</bold> seems likely to interfere with cellular
uptake by RFC, although the 6-methyl group does not appear to compromise
the binding and transport of <bold>5</bold> by PCFT or FRs &#x003b1;
or &#x003b2;. Similar simulations with compounds <bold>6</bold>&#x02013;<bold>8</bold> provided identical conclusions (see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.3c00326/suppl_file/ml3c00326_si_001.pdf">Figure S1</ext-link> in the Supporting Information).</p><fig id="fig3" position="float"><label>Figure 3</label><caption><p><bold>Docked poses of
1 (PMX, green) and 5 (6-methyl PMX analogue,
purple) in binding pockets of (a, b) PCFT, (c, d) FR&#x003b1;, (e, f)
FR&#x003b2;, and (g, h) RFC.</bold> The ligands in (g, h) are shown
180&#x000b0; horizontally flipped compared to (a&#x02013;f) for a better
view in the RFC binding pocket.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ml3c00326_0003" id="gr3" position="float"/></fig><p>To assess the 6-methyl moiety&#x02019;s ability
to restrict movement
of the flexible 5-substituent compared to the 6-unsubstituted analogues,
we performed a low-mode conformational search (LMCS) using MacroModel.<sup><xref ref-type="bibr" rid="ref38">38</xref></sup> Conformations within 5 kcal/mol of the lowest-energy
conformer were generated. The conformation numbers obtained for each
of the energy-minimized compounds (in parentheses) are as follows: <bold>1</bold> (268) vs <bold>5</bold> (243); <bold>2</bold> (605) vs <bold>6</bold> (535); <bold>3</bold> (359) vs <bold>7</bold> (281); and <bold>4</bold> (339) vs <bold>8</bold> (299). Thus, compared to the parent
6-des-methyl pyrrolo[2,3-<italic>d</italic>]pyrimidine compounds <bold>1</bold>&#x02013;<bold>4</bold>, the corresponding 6-methyl compounds <bold>5</bold>&#x02013;<bold>8</bold> exhibit substantially fewer conformations.</p><p>For the synthesis, nucleophilic aromatic substitution of the commercially
available 2-amino-6-chloropyrimidin-4(3<italic>H</italic>)-one <bold>9</bold> (<xref rid="sch1" ref-type="scheme">Scheme <xref rid="sch1" ref-type="scheme">1</xref></xref>) with hydrazine hydrate afforded the intermediate hydrazine <bold>10</bold>.<sup><xref ref-type="bibr" rid="ref32">32</xref></sup></p><fig id="sch1" position="float"><label>Scheme 1</label><caption><p id="s1fn1">Reagents and conditions:
(a)
Hydrazine hydrate, H<sub>2</sub>O, reflux, 3 h, 72%.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ml3c00326_0005" id="gr5" position="float"/></fig><p>Palladium-catalyzed Heck coupling of commercially available
starting
materials <bold>11a</bold> and <bold>11c</bold> (<xref rid="sch2" ref-type="scheme">Scheme <xref rid="sch2" ref-type="scheme">2</xref></xref>) and alkenol <bold>12</bold> gave the coupled, unsaturated secondary alcohols that rearranged
to the vinyl alcohols and tautomerized to afford the ketones <bold>17a</bold> and <bold>17c</bold>. A similar Heck coupling of <bold>11a</bold> with alkenone <bold>13</bold> provided an unsaturated
ketone <bold>14</bold> which underwent catalytic hydrogenation to
give <bold>17b</bold>. The ketone intermediate <bold>17d</bold> was
synthesized using a modified Heck coupling reaction between <bold>11d</bold> and alkenol <bold>12</bold>, employing an electron-rich
phosphine ligand.</p><fig id="sch2" position="float"><label>Scheme 2</label><caption><p id="s2fn1">Reagents and conditions:
(a)
Bu<sub>4</sub>NCl, Pd(OAc)<sub>2</sub>, LiCl, LiOAc, or KOAc, DMF,
80 &#x000b0;C, 3&#x02013;16 h, 64&#x02013;97% (Z = I or Br); (b) 5% Pd/C,
H<sub>2</sub>, 35 psi, rt, 24 h, 90&#x02013;95%; (c) 2-(di-<italic>tert</italic>-butylphosphino)-1-phenylindole, Pd(dba)<sub>2</sub>, TEA, 80 &#x000b0;C, 2 h, 52%; (d) DMP, CHCl<sub>3</sub>, 3 h, rt,
67%.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ml3c00326_0006" id="gr6" position="float"/></fig><p>A key step in the synthesis of the 5-substituted
2-amino-4-oxo-6-methyl
pyrrolo[2,3-<italic>d</italic>]pyrimidine classical antifolates involved
thermal indolization of the hydrazones <bold>18a</bold>&#x02013;<bold>d</bold><sup><xref ref-type="bibr" rid="ref32">32</xref></sup> (<xref rid="sch3" ref-type="scheme">Scheme <xref rid="sch3" ref-type="scheme">3</xref></xref>). Condensation of the ketones <bold>17a</bold>&#x02013;<bold>d</bold> with the hydrazine <bold>10</bold> under reflux
in 2-methoxyethanol afforded the key pyrimidine hydrazone intermediates <bold>18a</bold>&#x02013;<bold>d</bold>.<sup><xref ref-type="bibr" rid="ref32">32</xref></sup> Fischer
indole cyclization of hydrazones <bold>18a</bold>&#x02013;<bold>d</bold> was accomplished regioselectively to the 5-substituted, 2-amino-4-oxo-6-methyl
pyrrolo[2,3-<italic>d</italic>]pyrimidines <bold>19a</bold>&#x02013;<bold>d</bold> by thermolysis in diphenyl ether. <sup>1</sup>H NMR showed
no evidence of the presence of the other possible 6-substituted regioisomer
(a key determinant is the presence of a C6-CH<sub>3</sub> chemical
shift). The aromatic esters of <bold>19a</bold>&#x02013;<bold>d</bold> were subjected to base-catalyzed hydrolysis to afford pteroic acids <bold>20a</bold>&#x02013;<bold>d</bold>. Compounds <bold>20a</bold>&#x02013;<bold>d</bold> were subsequently coupled with <sc>l</sc>-glutamate diesters
to afford <bold>21a</bold>&#x02013;<bold>d</bold>. Final saponification
of diesters <bold>21a</bold>&#x02013;<bold>d</bold> with 1 N NaOH,
followed by neutralization and acidification to pH 4 in the cold,
provided target compounds <bold>5</bold>&#x02013;<bold>8</bold>.</p><fig id="sch3" position="float"><label>Scheme 3</label><caption><p id="s3fn1">Reagents and conditions:
(a)
2-methoxyethanol, reflux, 14 h, 56&#x02013;89%; (b) Ph<sub>2</sub>O,
240 &#x000b0;C, or reflux, 5&#x02013;8 h, 12&#x02013;77%; (c) 1 N NaOH,
rt, 12 h, 63&#x02013;94%; (d) Dimethyl- or diethyl-<sc>l</sc>-glutamate,
(i) NMM, CDMT, DMF, rt or 40 &#x000b0;C, 8&#x02013;12 h, 30&#x02013;78%
or (ii) isobutyl chloroformate, TEA, DMF, 0 &#x000b0;C, to rt, 60 h,
61% ; (e) (i) 1 N NaOH, rt, 1&#x02013;24 h; (ii) 0&#x02013;4 &#x000b0;C,
1 N HCl, 19&#x02013;80%.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ml3c00326_0007" id="gr7" position="float"/></fig><p>For desmethyl compound <bold>4</bold>, a different synthetic strategy
was used. A Sonogashira coupling reaction between bromofluorobenzoate <bold>11d</bold> and unsaturated alkynol <bold>22</bold> afforded <bold>23</bold> (<xref rid="sch4" ref-type="scheme">Scheme <xref rid="sch4" ref-type="scheme">4</xref></xref>), followed by hydrogenation and oxidation to obtain aldehyde <bold>25</bold>. Bromination afforded <bold>26</bold>, which was immediately
condensed with 2,6-diamino-4-oxo-pyrimidine at 45 &#x000b0;C to afford
the 5-substituted pyrrolo[2,3-<italic>d</italic>]pyrimidine <bold>27</bold>. Ester hydrolysis of <bold>27</bold>, followed by the amide
coupling of <bold>28</bold> with <sc>l</sc>-glutamate diethyl ester
hydrochloride, afforded <bold>29</bold>. The diester <bold>29</bold> was hydrolyzed with 1 N NaOH, followed by acidification to pH 4
at 0&#x02013;4 &#x000b0;C, to provide compound <bold>4</bold>.</p><fig id="sch4" position="float"><label>Scheme 4</label><caption><p id="s4fn1">Reagents and conditions:
(a)
CuI, PdCl<sub>2</sub>, PPh<sub>3</sub>, Et<sub>3</sub>N, CH<sub>3</sub>CN, microwave, 100 &#x000b0;C, 1 h, 63%; (b) 10% Pd/C, H<sub>2</sub>, 55 psi, MeOH, rt, 9 h, 95%; (c) Dess-Martin Periodinane, CH<sub>2</sub>Cl<sub>2</sub>, 0 &#x000b0;C; to rt, 3 h, 45%, (d) Br<sub>2</sub>, 1,4-dioxane, CH<sub>2</sub>Cl<sub>2</sub>, rt, 3 h; (e) 2,6-diaminopyrimidin-4(3<italic>H</italic>)-one, CH<sub>3</sub>COONa, MeOH, 45 &#x000b0;C; 12 h, 46%
over two steps; (f) 1 N NaOH, rt, 3 h, 96%; (g) <italic>N</italic>-methylmorpholine, 2-chloro-4,6-dimethoxy-1,3,5-triazine, <sc>l</sc>-glutamate diethyl ester hydrochloride, DMF, rt, 12 h, 59%;(h) (i)
1 N, NaOH, rt, 3 h; (ii) 0&#x02013;4 &#x000b0;C, 1 N HCl, 56%.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ml3c00326_0008" id="gr8" position="float"/></fig><p>To assess the impact of 6-methyl substitutions on
the bicyclic
scaffolds of the pyrrolo[2,3-<italic>d</italic>]pyrimidine antifolates <bold>1</bold>&#x02013;<bold>4</bold> on RFC transport vis-&#x000e0;-vis
PCFT, FR&#x003b1;, and FR&#x003b2;, we used a unique biological readout
for transport activity. This involved proliferation assays with isogenic
Chinese hamster ovary (CHO) sublines derived from RFC-, FR-, and PCFT-null
MTXRIIOua<sup>R</sup>2&#x02013;4 CHO cells<sup><xref ref-type="bibr" rid="ref39">39</xref>,<xref ref-type="bibr" rid="ref40">40</xref></sup> engineered to express the human FR&#x003b1; (RT16),<sup><xref ref-type="bibr" rid="ref25">25</xref></sup> FR&#x003b2; (D4),<sup><xref ref-type="bibr" rid="ref25">25</xref></sup> RFC (PC43&#x02013;10),<sup><xref ref-type="bibr" rid="ref41">41</xref></sup> or PCFT (R2/PCFT4).<sup><xref ref-type="bibr" rid="ref26">26</xref>,<xref ref-type="bibr" rid="ref42">42</xref></sup> As these CHO cell lines are genetically identical except for their
folate transporters, differences in inhibition of cell proliferation
by specific cytotoxic antifolates directly reflect transporter specificities.<sup><xref ref-type="bibr" rid="ref19">19</xref>,<xref ref-type="bibr" rid="ref23">23</xref>&#x02212;<xref ref-type="bibr" rid="ref31">31</xref>,<xref ref-type="bibr" rid="ref42">42</xref></sup></p><p>RFC-expressing PC43&#x02013;10
cells were potently inhibited by
the 5-substituted pyrrolo[2,3-<italic>d</italic>]pyrimidine compounds <bold>1</bold>&#x02013;<bold>4</bold> with half-maximal inhibitory concentration
(IC<sub>50</sub>) values that ranged from 31 to 169 nM (<xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>). This extended to FR&#x003b1;-expressing
RT16 (IC<sub>50</sub> values of 6.8&#x02013;550 nM), FR&#x003b2;-expressing
D4 (IC<sub>50</sub> values of 3.5&#x02013;552 nM), and PCFT-expressing
R2/PCFT4 (22&#x02013;329 nM) cells. We discovered that for the corresponding
6-methyl substituted pyrrolo[2,3-<italic>d</italic>]pyrimidine analogues <bold>5</bold>&#x02013;<bold>8</bold>, RFC-mediated cell inhibition was
uniformly abolished (IC<sub>50</sub> &#x0003e; 1000 nM), with modest effects
on FR&#x003b1; (RT16 IC<sub>50</sub>s from 2.5&#x02013;100 nM) and FR&#x003b2;
(D4 IC<sub>50</sub>s from 2.6&#x02013;49 nM) (<xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>). For PCFT-expressing R2/PCFT4 cells, 6-methyl
pyrrole substitution completely preserved (<bold>7</bold>) or slightly
increased (<bold>5</bold>, <bold>6</bold>) inhibition potencies (relative
to compounds <bold>3</bold>, <bold>1</bold>, and <bold>2</bold>, respectively).
However, the 6-methyl substitution in compound <bold>8</bold> abolished
PCFT activity altogether. Transport specificities are further reflected
in &#x0201c;Specificity Ratios&#x0201d;, defined as the ratios of IC<sub>50</sub> values for PC43&#x02013;10 (RFC) to those for R2/PCFT4 (PCFT),
RT16 (FR&#x003b1;), or D4 (FR&#x003b2;) cells (<xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>). Thus, our rationale to provide steric
hindrance with a 6-methyl moiety to impede attachment to the RFC was
indeed realized.</p><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><title><bold>Cell Proliferation (IC</bold><sub><bold>50</bold></sub><bold>nM) Assays with 6-Methyl 5-substituted
Pyrrolo[2,3-</bold><italic>d</italic><bold>]pyrimidine Analogues</bold><xref rid="tbl1-fn1" ref-type="table-fn">a</xref></title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ml3c00326_0009" id="gr9" position="float"/><table-wrap-foot><fn id="tbl1-fn1"><label>a</label><p>Growth inhibition assays were
performed using CHO sublines derived from RFC-, PCFT-, and FR-null
MTXRIIOuaR2-4 CHO cells (R2)<sup><xref ref-type="bibr" rid="ref39">39</xref>,<xref ref-type="bibr" rid="ref40">40</xref></sup> engineered to express
human RFC (PC43-10),<sup><xref ref-type="bibr" rid="ref41">41</xref></sup> PCFT (R2/PCFT4),<sup><xref ref-type="bibr" rid="ref26">26</xref>,<xref ref-type="bibr" rid="ref42">42</xref></sup> FR&#x003b1; (RT16),<sup><xref ref-type="bibr" rid="ref25">25</xref></sup> or FR&#x003b2; (D4).<sup><xref ref-type="bibr" rid="ref25">25</xref></sup> Human cell lines include KB nasopharengeal carcinoma
cells, IGROV1 ovarian cancer cells,<sup><xref ref-type="bibr" rid="ref46">46</xref></sup> and
IOSE 7576 normal ovary cells.<sup><xref ref-type="bibr" rid="ref43">43</xref></sup> Experimental
methods are described in the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.3c00326/suppl_file/ml3c00326_si_001.pdf">Supporting Information</ext-link> and were previously published.<sup><xref ref-type="bibr" rid="ref23">23</xref>&#x02212;<xref ref-type="bibr" rid="ref26">26</xref>,<xref ref-type="bibr" rid="ref28">28</xref>&#x02212;<xref ref-type="bibr" rid="ref31">31</xref>,<xref ref-type="bibr" rid="ref35">35</xref>,<xref ref-type="bibr" rid="ref42">42</xref></sup> Results are shown as mean values from three to five experiments
(&#x000b1; standard errors) and are presented as the calculated IC<sub>50</sub> values representing the concentrations at which growth of
50% of cells was inhibited relative to untreated cells. &#x0201c;Selectivity
Ratios&#x0201d; are ratios of IC<sub>50</sub> values from the respective
CHO sublines.</p></fn></table-wrap-foot></table-wrap><p><xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref> also shows
the inhibition of proliferation of KB human nasopharyngeal carcinoma
cells and IGROV1 epithelial ovarian cancer cells, both of which express
RFC, PCFT, and FR&#x003b1;.<sup><xref ref-type="bibr" rid="ref27">27</xref>,<xref ref-type="bibr" rid="ref42">42</xref></sup> Results are compared
to those with IOSE 7576 normal ovary cells<sup><xref ref-type="bibr" rid="ref43">43</xref></sup> which express RFC comparable to IGROV1 cells accompanying low levels
of PCFT (&#x0223c;30% of IGROV1) and undetectable FR&#x003b1;. For the
tumor cells, except the des-methyl compound <bold>4</bold> with IGROV1
cells, all compounds were inhibitory. The 6-methyl substituted compounds
(<bold>5</bold>, <bold>6</bold>, and <bold>8</bold>) inhibited KB
cell proliferation with nanomolar IC<sub>50</sub> values only slightly
less than those for the nonmethylated 5-substituted (<bold>1</bold>, <bold>2</bold>, and <bold>4</bold>) pyrrolo[2,3-<italic>d</italic>]pyrimidine compounds. For both KB and IGROV1 cells, compound <bold>7</bold> was the most potent inhibitor with 242-fold and 127-fold,
respectively, greater potencies than the corresponding 6-desmethyl
analogue <bold>3</bold>.</p><p>Des-methyl compounds <bold>2</bold> and <bold>3</bold> were more
potent toward IOSE 7576 cells than IGROV1 cells (<xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>). Whereas compound <bold>1</bold> (PMX) was more active toward IGROV1 cells, <bold>4</bold> was inactive
toward both IGROV1 and IOSE 7576 cells. Notably, the 6-methyl-substituted
compounds <bold>5</bold>, <bold>7</bold>, and <bold>8</bold> were
far more potent than the corresponding des-methyl compounds (<bold>1</bold>, <bold>3</bold>, and <bold>4</bold>) toward IGROV1 cells.
Conversely, compounds <bold>5</bold>, <bold>7</bold>, and <bold>8</bold> were inert toward IOSE 7576 cells up to 1000 nM. Compound <bold>6</bold> was modestly inhibitory toward both IGROV1 and IOSE 7576
cells. Thus, 6-methyl substitution increases potency toward IGROV1
ovarian cancer cells over IOSE 7576 normal ovary cells.</p><p>To identify
the targeted pathways/enzymes of these pyrrolo[2,3-<italic>d</italic>]pyrimidine compounds (<bold>1</bold>, <bold>2</bold>, <bold>4</bold>&#x02013;<bold>8</bold>), <italic>in vitro</italic> growth
inhibition assays were performed with KB tumor cells in glycine-,
adenosine-, and thymidine-free media without additions or in the presence
of thymidine (10 &#x003bc;M), adenosine (60 &#x003bc;M), or glycine (130
&#x003bc;M) (both singly and in various combinations; <xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>).<sup><xref ref-type="bibr" rid="ref18">18</xref>,<xref ref-type="bibr" rid="ref23">23</xref>&#x02212;<xref ref-type="bibr" rid="ref25">25</xref>,<xref ref-type="bibr" rid="ref28">28</xref>&#x02212;<xref ref-type="bibr" rid="ref31">31</xref>,<xref ref-type="bibr" rid="ref42">42</xref>,<xref ref-type="bibr" rid="ref44">44</xref>,<xref ref-type="bibr" rid="ref45">45</xref></sup> For <italic>de novo</italic> purine biosynthesis
inhibitors, protection was also tested with AICA (320 &#x003bc;M), which
is metabolized to AICA ribonucleotide (substrate for the AICARFTase
reaction, thus circumventing GARFTase).</p><fig id="fig4" position="float"><label>Figure 4</label><caption><p><bold>Metabolite protection
experiments.</bold> To demonstrate
the intracellular target(s) for the pyrrolo[2,3-<italic>d</italic>]pyrimidine antifolates (<bold>1</bold>, <bold>2</bold>, <bold>4</bold>&#x02013;<bold>8</bold>), proliferation of KB cells was assayed in
the presence of the inhibitors with nucleosides (adenosine, thymidine),
glycine, and 5-aminoimidazole-4-carboxamide (AICA). Cell densities
were measured with a fluorescence assay<sup><xref ref-type="bibr" rid="ref25">25</xref></sup> and a fluorescence plate reader. Results were normalized to cell
densities in the absence of drug. Results shown are mean values plus/minus
standard errors from triplicate experiments. Experimental details
are described in the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.3c00326/suppl_file/ml3c00326_si_001.pdf">Supporting Information</ext-link>, and the methods have been previously published.<sup><xref ref-type="bibr" rid="ref18">18</xref>,<xref ref-type="bibr" rid="ref23">23</xref>&#x02212;<xref ref-type="bibr" rid="ref25">25</xref>,<xref ref-type="bibr" rid="ref28">28</xref>&#x02212;<xref ref-type="bibr" rid="ref31">31</xref>,<xref ref-type="bibr" rid="ref42">42</xref>,<xref ref-type="bibr" rid="ref44">44</xref></sup></p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ml3c00326_0004" id="gr4" position="float"/></fig><p>The 5-subsituted pyrrolo[2,3-<italic>d</italic>]pyrimidine compounds
showed patterns of metabolite protection consistent with the inhibition
of multiple C1 pathways. Interestingly, compounds <bold>2</bold> and <bold>4</bold> like PMX (<bold>1</bold>) consistently inhibited both thymidylate
and purine nucleotide biosynthesis (protected by adenosine and thymidine),
the latter most likely at AICARFTase as well as at GARFTase (protection
by AICA).<sup><xref ref-type="bibr" rid="ref23">23</xref>&#x02212;<xref ref-type="bibr" rid="ref25">25</xref>,<xref ref-type="bibr" rid="ref28">28</xref>&#x02212;<xref ref-type="bibr" rid="ref31">31</xref>,<xref ref-type="bibr" rid="ref35">35</xref>,<xref ref-type="bibr" rid="ref42">42</xref></sup> For compound <bold>2</bold>, addition of glycine provided greater
protection than did adenosine and thymidine alone. This suggests an
inhibition of mitochondrial C1 metabolism in addition to nucleotide
biosynthesis in the cytosol.<sup><xref ref-type="bibr" rid="ref45">45</xref></sup> Conversely,
the 6-methyl-substituted compounds <bold>5</bold>&#x02013;<bold>8</bold> were exclusive inhibitors of <italic>de novo</italic> purine biosynthesis
(protected by adenosine alone), most likely at GARFTase (protected
by AICA).<sup><xref ref-type="bibr" rid="ref23">23</xref>&#x02212;<xref ref-type="bibr" rid="ref25">25</xref>,<xref ref-type="bibr" rid="ref28">28</xref>&#x02212;<xref ref-type="bibr" rid="ref31">31</xref>,<xref ref-type="bibr" rid="ref35">35</xref>,<xref ref-type="bibr" rid="ref42">42</xref></sup></p><p>In summary, a methyl group plays a vital role in the molecular
recognition of endogenous and exogenous ligands by receptors.<sup><xref ref-type="bibr" rid="ref47">47</xref></sup> Further, the steric and electronic effects of
a methyl group can influence selective ligand binding and increased
potency, among various other pharmacologic effects.<sup><xref ref-type="bibr" rid="ref48">48</xref>&#x02212;<xref ref-type="bibr" rid="ref50">50</xref></sup></p><p>In the
current study, we synthesized 6-methyl 5-substituted pyrrolo[2,3-<italic>d</italic>]pyrimidine compounds (<bold>5</bold>, <bold>6</bold>, <bold>7</bold>, and <bold>8</bold>) as tumor-targeted antifolates based
on the structures of the nonmethylated 5-substituted pyrrolo[2,3-<italic>d</italic>]pyrimidine compounds <bold>1</bold>, <bold>2</bold>, <bold>3</bold>, and <bold>4</bold>.<sup><xref ref-type="bibr" rid="ref23">23</xref>,<xref ref-type="bibr" rid="ref24">24</xref>,<xref ref-type="bibr" rid="ref3">3</xref></sup> Our goal was to explore the impact of 6-methyl substitutions on
drug uptake and cell inhibition mediated by RFC vis &#x000e1; vis more
tumor-selective PCFT, FR&#x003b1;, and FR&#x003b2;.<sup><xref ref-type="bibr" rid="ref3">3</xref>,<xref ref-type="bibr" rid="ref4">4</xref>,<xref ref-type="bibr" rid="ref6">6</xref>,<xref ref-type="bibr" rid="ref8">8</xref>,<xref ref-type="bibr" rid="ref13">13</xref>,<xref ref-type="bibr" rid="ref21">21</xref></sup> A compelling rationale
for our study was provided from molecular modeling of our pyrrolo[2,3-<italic>d</italic>]pyrimidine antifolates in the RFC structure<sup><xref ref-type="bibr" rid="ref37">37</xref></sup> which indicated a steric clash of the 6-methyl
moiety of compounds <bold>5</bold>&#x02013;<bold>8</bold> with Tyr126
in the RFC binding site; no analogous feature was seen for PCFT or
for FRs &#x003b1; or &#x003b2;. As a biological readout of transport,
we used our isogenic panel of CHO sublines.<sup><xref ref-type="bibr" rid="ref25">25</xref>,<xref ref-type="bibr" rid="ref41">41</xref>,<xref ref-type="bibr" rid="ref42">42</xref></sup></p><p>Consistent with our prior studies,<sup><xref ref-type="bibr" rid="ref23">23</xref>,<xref ref-type="bibr" rid="ref24">24</xref></sup> we confirmed
that 5-substituted pyrrolo[2,3-<italic>d</italic>]pyrimidine antifolates <bold>1</bold>&#x02013;<bold>4</bold> without 6-methyl substitutions exhibited
promiscuous transport by RFC as well as by PCFT and FRs &#x003b1; and
&#x003b2;. In KB cells, the loss of cell proliferation reflected inhibition
of thymidylate biosynthesis and purine nucleotide biosynthesis at
both GARFTase and AICARFTase. For compound <bold>2</bold>, inhibition
of mitochondrial C1 metabolism was also suggested. We discovered that
6-methyl-substituted pyrrolo[2,3-<italic>d</italic>]pyrimidine antifolates <bold>5</bold>&#x02013;<bold>8</bold> are distinctly selective for transport
by PCFT and FRs over RFC and exclusively target <italic>de novo</italic> purine biosynthesis at GARFTase.<sup><xref ref-type="bibr" rid="ref25">25</xref>,<xref ref-type="bibr" rid="ref28">28</xref>&#x02212;<xref ref-type="bibr" rid="ref31">31</xref></sup> Selectivity ratios for the 6-methyl compounds with PCFT ranged from
&#x0003e;15.5 (<bold>6</bold>) to &#x0003e;130 (<bold>5</bold>), whereas for
FR&#x003b1;
selectivity ranged from &#x0003e;10 (<bold>8</bold>) to &#x0003e;395 (<bold>7</bold>). For FR&#x003b2;, selectivity ratios ranged from &#x0003e;20 (<bold>8</bold>) to &#x0003e;383 (<bold>6</bold>). Inhibition of cell proliferation
by the
6-methyl-substituted pyrrolo[2,3-<italic>d</italic>]pyrimidine antifolates <bold>5</bold>&#x02013;<bold>8</bold> was extended to IGROV1 cells with
comparison to IOSE 7576 cells, demonstrating that the 6-methyl substitution
promotes tumor selectivity.</p><p>In conclusion, we established that
6-methyl substitutions on the
pyrrole ring of 5-substituted pyrrolo[2,3-<italic>d</italic>]pyrimidine
analogues preserved or increased inhibitor potencies and tumor selectivity,
while positively impacting drug uptake by FRs and PCFT over RFC. Improved
target selectivity, potency, and modified mechanisms-of-action (including
multienzyme inhibition) provide compelling evidence of the profound
impact of minor structural alterations in antitumor drug polypharmacology
for tumor-targeted pyrrolo[2,3-<italic>d</italic>]pyrimidine antifolates.
Clearly, the 6-methyl group provides an elegantly simple structural
solution that would afford significant advantages over current clinically
used antifolates.</p></body><back><notes id="notes1" notes-type="si"><title>Supporting Information Available</title><p>The Supporting Information is
available free of charge at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/10.1021/acsmedchemlett.3c00326?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsmedchemlett.3c00326</ext-link>.<list id="silist" list-type="simple"><list-item><p>Additional molecular modeling figures, synthetic experimental
details, and biological assay methods (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.3c00326/suppl_file/ml3c00326_si_001.pdf">PDF</ext-link>)</p></list-item></list></p></notes><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="sifile1"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ml3c00326_si_001.pdf"><caption><p>ml3c00326_si_001.pdf</p></caption></media></supplementary-material></sec><notes notes-type="" id="notes2"><title>Author Contributions</title><p><sup>&#x022a5;</sup> These authors contributed equally to this
work.</p></notes><notes notes-type="COI-statement" id="NOTES-d14e1378-autogenerated"><p>The authors
declare no
competing financial interest.</p></notes><ack><title>Acknowledgments</title><p>This work was supported by grants R01 CA250469 (L.H.
Matherly, A. Gangjee) and R01 CA53535 (L.H. Matherly, Z. Hou) from
the National Cancer Institute, the Eunice and Milton Ring Endowed
Chair for Cancer Research (L.H. Matherly), and the Duquesne University
Adrian Van Kaam Chair in Scholarly Excellence (Aleem Gangjee).</p></ack><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="journal" id="cit1"><name><surname>Ducker</surname><given-names>G. S.</given-names></name>; <name><surname>Rabinowitz</surname><given-names>J. D.</given-names></name>
<article-title>One-Carbon Metabolism in Health and Disease</article-title>. <source>Cell Metab</source>
<year>2017</year>, <volume>25</volume>, <fpage>27</fpage>&#x02013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmet.2016.08.009</pub-id>.<pub-id pub-id-type="pmid">27641100</pub-id>
</mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="journal" id="cit2"><name><surname>Visentin</surname><given-names>M.</given-names></name>; <name><surname>Zhao</surname><given-names>R.</given-names></name>; <name><surname>Goldman</surname><given-names>I. D.</given-names></name>
<article-title>The antifolates</article-title>. <source>Hematol Oncol Clin North Am.</source>
<year>2012</year>, <volume>26</volume>, <fpage>629</fpage>&#x02013;<lpage>48</lpage>. <pub-id pub-id-type="doi">10.1016/j.hoc.2012.02.002</pub-id>.<pub-id pub-id-type="pmid">22520983</pub-id>
</mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="journal" id="cit3"><name><surname>Matherly</surname><given-names>L. H.</given-names></name>; <name><surname>Wilson</surname><given-names>M. R.</given-names></name>; <name><surname>Hou</surname><given-names>Z.</given-names></name>
<article-title>The major
facilitative folate transporters
solute carrier 19A1 and solute carrier 46A1: biology and role in antifolate
chemotherapy of cancer</article-title>. <source>Drug Metab. Dispos.</source>
<year>2014</year>, <volume>42</volume>, <fpage>632</fpage>&#x02013;<lpage>49</lpage>. <pub-id pub-id-type="doi">10.1124/dmd.113.055723</pub-id>.<pub-id pub-id-type="pmid">24396145</pub-id>
</mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal" id="cit4"><name><surname>Elnakat</surname><given-names>H.</given-names></name>; <name><surname>Ratnam</surname><given-names>M.</given-names></name>
<article-title>Distribution, functionality
and gene regulation of
folate receptor isoforms: implications in targeted therapy</article-title>. <source>Advanced drug delivery reviews</source>
<year>2004</year>, <volume>56</volume>, <fpage>1067</fpage>&#x02013;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1016/j.addr.2004.01.001</pub-id>.<pub-id pub-id-type="pmid">15094207</pub-id>
</mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal" id="cit5"><name><surname>Matherly</surname><given-names>L. H.</given-names></name>; <name><surname>Hou</surname><given-names>Z.</given-names></name>; <name><surname>Deng</surname><given-names>Y.</given-names></name>
<article-title>Human reduced
folate carrier: translation of basic
biology to cancer etiology and therapy</article-title>. <source>Cancer
metastasis reviews</source>
<year>2007</year>, <volume>26</volume>, <fpage>111</fpage>&#x02013;<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1007/s10555-007-9046-2</pub-id>.<pub-id pub-id-type="pmid">17334909</pub-id>
</mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal" id="cit6"><name><surname>Matherly</surname><given-names>L. H.</given-names></name>; <name><surname>Hou</surname><given-names>Z.</given-names></name>; <name><surname>Gangjee</surname><given-names>A.</given-names></name>
<article-title>The promise and challenges
of exploiting the proton-coupled
folate transporter for selective therapeutic targeting of cancer</article-title>. <source>Cancer chemotherapy and pharmacology</source>
<year>2018</year>, <volume>81</volume>, <fpage>1</fpage>&#x02013;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1007/s00280-017-3473-8</pub-id>.<pub-id pub-id-type="pmid">29127457</pub-id>
</mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal" id="cit7"><name><surname>Zhao</surname><given-names>R.</given-names></name>; <name><surname>Goldman</surname><given-names>I. D.</given-names></name>
<article-title>The molecular identity
and characterization of a Proton-coupled
Folate Transporter-PCFT; biological ramifications and impact on the
activity of pemetrexed</article-title>. <source>Cancer metastasis reviews</source>
<year>2007</year>, <volume>26</volume>, <fpage>129</fpage>&#x02013;<lpage>39</lpage>. <pub-id pub-id-type="doi">10.1007/s10555-007-9047-1</pub-id>.<pub-id pub-id-type="pmid">17340171</pub-id>
</mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="book" id="cit8"><person-group person-group-type="allauthors"><name><surname>Kamen</surname><given-names>B. A.</given-names></name></person-group><article-title>Folate Receptors
and Therapeutic Applications</article-title>. In <source>Targeted
Drug Strategies for Cancer and Inflammation</source><italic>;</italic><person-group person-group-type="editor"><name><surname>Jackman</surname><given-names>A. L.</given-names></name>, <name><surname>Leamon</surname><given-names>C. P.</given-names></name></person-group>, Eds.; <publisher-name>Springer US</publisher-name>: <publisher-loc>Boston, MA</publisher-loc>, <year>2011</year>; pp <fpage>35</fpage>&#x02013;<lpage>47</lpage>.</mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal" id="cit9"><name><surname>Zhao</surname><given-names>R.</given-names></name>; <name><surname>Diop-Bove</surname><given-names>N.</given-names></name>; <name><surname>Visentin</surname><given-names>M.</given-names></name>; <name><surname>Goldman</surname><given-names>I. D.</given-names></name>
<article-title>Mechanisms of membrane
transport of folates into cells and across epithelia</article-title>. <source>Annu. Rev. Nutr</source>
<year>2011</year>, <volume>31</volume>, <fpage>177</fpage>&#x02013;<lpage>201</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-nutr-072610-145133</pub-id>.<pub-id pub-id-type="pmid">21568705</pub-id>
</mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal" id="cit10"><name><surname>Kamen</surname><given-names>B. A.</given-names></name>; <name><surname>Wang</surname><given-names>M. T.</given-names></name>; <name><surname>Streckfuss</surname><given-names>A. J.</given-names></name>; <name><surname>Peryea</surname><given-names>X.</given-names></name>; <name><surname>Anderson</surname><given-names>R. G.</given-names></name>
<article-title>Delivery
of folates to the cytoplasm of MA104 cells is mediated by a surface
membrane receptor that recycles</article-title>. <source>J. Biol. Chem.</source>
<year>1988</year>, <volume>263</volume>, <fpage>13602</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/S0021-9258(18)68284-5</pub-id>.<pub-id pub-id-type="pmid">3417674</pub-id>
</mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal" id="cit11"><name><surname>Zhao</surname><given-names>R.</given-names></name>; <name><surname>Goldman</surname><given-names>I. D.</given-names></name>
<article-title>Resistance to antifolates</article-title>. <source>Oncogene</source>
<year>2003</year>, <volume>22</volume>, <fpage>7431</fpage>&#x02013;<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1038/sj.onc.1206946</pub-id>.<pub-id pub-id-type="pmid">14576850</pub-id>
</mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal" id="cit12"><name><surname>Qiu</surname><given-names>A.</given-names></name>; <name><surname>Jansen</surname><given-names>M.</given-names></name>; <name><surname>Sakaris</surname><given-names>A.</given-names></name>; <name><surname>Min</surname><given-names>S. H.</given-names></name>; <name><surname>Chattopadhyay</surname><given-names>S.</given-names></name>; <name><surname>Tsai</surname><given-names>E.</given-names></name>; <name><surname>Sandoval</surname><given-names>C.</given-names></name>; <name><surname>Zhao</surname><given-names>R.</given-names></name>; <name><surname>Akabas</surname><given-names>M. H.</given-names></name>; <name><surname>Goldman</surname><given-names>I. D.</given-names></name>
<article-title>Identification of an intestinal folate transporter
and the molecular basis for hereditary folate malabsorption</article-title>. <source>Cell</source>
<year>2006</year>, <volume>127</volume>, <fpage>917</fpage>&#x02013;<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2006.09.041</pub-id>.<pub-id pub-id-type="pmid">17129779</pub-id>
</mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal" id="cit13"><name><surname>Desmoulin</surname><given-names>S. K.</given-names></name>; <name><surname>Hou</surname><given-names>Z.</given-names></name>; <name><surname>Gangjee</surname><given-names>A.</given-names></name>; <name><surname>Matherly</surname><given-names>L. H.</given-names></name>
<article-title>The human proton-coupled folate transporter:
Biology and therapeutic applications to cancer</article-title>. <source>Cancer Biol. Ther</source>
<year>2012</year>, <volume>13</volume>, <fpage>1355</fpage>&#x02013;<lpage>1373</lpage>. <pub-id pub-id-type="doi">10.4161/cbt.22020</pub-id>.<pub-id pub-id-type="pmid">22954694</pub-id>
</mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal" id="cit14"><name><surname>Qiu</surname><given-names>A.</given-names></name>; <name><surname>Min</surname><given-names>S. H.</given-names></name>; <name><surname>Jansen</surname><given-names>M.</given-names></name>; <name><surname>Malhotra</surname><given-names>U.</given-names></name>; <name><surname>Tsai</surname><given-names>E.</given-names></name>; <name><surname>Cabelof</surname><given-names>D. C.</given-names></name>; <name><surname>Matherly</surname><given-names>L. H.</given-names></name>; <name><surname>Zhao</surname><given-names>R.</given-names></name>; <name><surname>Akabas</surname><given-names>M. H.</given-names></name>; <name><surname>Goldman</surname><given-names>I. D.</given-names></name>
<article-title>Rodent intestinal folate transporters (SLC46A1): secondary
structure, functional properties, and response to dietary folate restriction</article-title>. <source>Am. J. Physiol Cell Physiol</source>
<year>2007</year>, <volume>293</volume>, <fpage>C1669</fpage>&#x02013;<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1152/ajpcell.00202.2007</pub-id>.<pub-id pub-id-type="pmid">17898134</pub-id>
</mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal" id="cit15"><name><surname>Zhao</surname><given-names>R.</given-names></name>; <name><surname>Matherly</surname><given-names>L. H.</given-names></name>; <name><surname>Goldman</surname><given-names>I. D.</given-names></name>
<article-title>Membrane
transporters and folate
homeostasis: intestinal absorption and transport into systemic compartments
and tissues</article-title>. <source>Expert reviews in molecular medicine</source>
<year>2009</year>, <volume>11</volume>, <elocation-id>e4</elocation-id><pub-id pub-id-type="doi">10.1017/S1462399409000969</pub-id>.<pub-id pub-id-type="pmid">19173758</pub-id>
</mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal" id="cit16"><name><surname>Zhao</surname><given-names>R.</given-names></name>; <name><surname>Visentin</surname><given-names>M.</given-names></name>; <name><surname>Suadicani</surname><given-names>S. O.</given-names></name>; <name><surname>Goldman</surname><given-names>I. D.</given-names></name>
<article-title>Inhibition of the
proton-coupled folate transporter (PCFT-SLC46A1) by bicarbonate and
other anions</article-title>. <source>Mol. Pharmacol.</source>
<year>2013</year>, <volume>84</volume>, <fpage>95</fpage>&#x02013;<lpage>103</lpage>. <pub-id pub-id-type="doi">10.1124/mol.113.085605</pub-id>.<pub-id pub-id-type="pmid">23609145</pub-id>
</mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="journal" id="cit17"><name><surname>Giovannetti</surname><given-names>E.</given-names></name>; <name><surname>Zucali</surname><given-names>P. A.</given-names></name>; <name><surname>Assaraf</surname><given-names>Y. G.</given-names></name>; <name><surname>Funel</surname><given-names>N.</given-names></name>; <name><surname>Gemelli</surname><given-names>M.</given-names></name>; <name><surname>Stark</surname><given-names>M.</given-names></name>; <name><surname>Thunnissen</surname><given-names>E.</given-names></name>; <name><surname>Hou</surname><given-names>Z.</given-names></name>; <name><surname>Muller</surname><given-names>I. B.</given-names></name>; <name><surname>Struys</surname><given-names>E. A.</given-names></name>; <name><surname>Perrino</surname><given-names>M.</given-names></name>; <name><surname>Jansen</surname><given-names>G.</given-names></name>; <name><surname>Matherly</surname><given-names>L. H.</given-names></name>; <name><surname>Peters</surname><given-names>G. J.</given-names></name>
<article-title>Role of proton-coupled folate transporter
in pemetrexed
resistance of mesothelioma: clinical evidence and new pharmacological
tools</article-title>. <source>Ann. Oncol</source>
<year>2017</year>, <volume>28</volume>, <fpage>2725</fpage>&#x02013;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1093/annonc/mdx499</pub-id>.<pub-id pub-id-type="pmid">28945836</pub-id>
</mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="journal" id="cit18"><name><surname>Dekhne</surname><given-names>A. S.</given-names></name>; <name><surname>Ning</surname><given-names>C.</given-names></name>; <name><surname>Nayeen</surname><given-names>M. J.</given-names></name>; <name><surname>Shah</surname><given-names>K.</given-names></name>; <name><surname>Kalpage</surname><given-names>H.</given-names></name>; <name><surname>Fr&#x000fc;hauf</surname><given-names>J.</given-names></name>; <name><surname>Wallace-Povirk</surname><given-names>A.</given-names></name>; <name><surname>O&#x02019;Connor</surname><given-names>C.</given-names></name>; <name><surname>Hou</surname><given-names>Z.</given-names></name>; <name><surname>Kim</surname><given-names>S.</given-names></name>; <name><surname>H&#x000fc;ttemann</surname><given-names>M.</given-names></name>; <name><surname>Gangjee</surname><given-names>A.</given-names></name>; <name><surname>Matherly</surname><given-names>L. H.</given-names></name>
<article-title>Cellular
Pharmacodynamics of a Novel Pyrrolo[3,2-<italic>d</italic>]pyrimidine
Inhibitor Targeting Mitochondrial and Cytosolic One-Carbon Metabolism</article-title>. <source>Mol. Pharmacol.</source>
<year>2020</year>, <volume>97</volume>, <fpage>9</fpage>&#x02013;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1124/mol.119.117937</pub-id>.<pub-id pub-id-type="pmid">31707355</pub-id>
</mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="journal" id="cit19"><name><surname>Wilson</surname><given-names>M. R.</given-names></name>; <name><surname>Hou</surname><given-names>Z.</given-names></name>; <name><surname>Yang</surname><given-names>S.</given-names></name>; <name><surname>Polin</surname><given-names>L.</given-names></name>; <name><surname>Kushner</surname><given-names>J.</given-names></name>; <name><surname>White</surname><given-names>K.</given-names></name>; <name><surname>Huang</surname><given-names>J.</given-names></name>; <name><surname>Ratnam</surname><given-names>M.</given-names></name>; <name><surname>Gangjee</surname><given-names>A.</given-names></name>; <name><surname>Matherly</surname><given-names>L. H.</given-names></name>
<article-title>Targeting
Nonsquamous Nonsmall Cell Lung Cancer via the Proton-Coupled Folate
Transporter with 6-Substituted Pyrrolo[2,3-d]Pyrimidine Thienoyl Antifolates</article-title>. <source>Mol. Pharmacol.</source>
<year>2016</year>, <volume>89</volume>, <fpage>425</fpage>&#x02013;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1124/mol.115.102798</pub-id>.<pub-id pub-id-type="pmid">26837243</pub-id>
</mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal" id="cit20"><name><surname>Hou</surname><given-names>Z.</given-names></name>; <name><surname>Gattoc</surname><given-names>L.</given-names></name>; <name><surname>O&#x02019;Connor</surname><given-names>C.</given-names></name>; <name><surname>Yang</surname><given-names>S.</given-names></name>; <name><surname>Wallace-Povirk</surname><given-names>A.</given-names></name>; <name><surname>George</surname><given-names>C.</given-names></name>; <name><surname>Orr</surname><given-names>S.</given-names></name>; <name><surname>Polin</surname><given-names>L.</given-names></name>; <name><surname>White</surname><given-names>K.</given-names></name>; <name><surname>Kushner</surname><given-names>J.</given-names></name>; <name><surname>Morris</surname><given-names>R. T.</given-names></name>; <name><surname>Gangjee</surname><given-names>A.</given-names></name>; <name><surname>Matherly</surname><given-names>L. H.</given-names></name>
<article-title>Dual Targeting
of Epithelial Ovarian Cancer Via Folate Receptor alpha and the Proton-Coupled
Folate Transporter with 6-Substituted Pyrrolo[2,3-d]pyrimidine Antifolates</article-title>. <source>Mol. Cancer Ther</source>
<year>2017</year>, <volume>16</volume>, <fpage>819</fpage>&#x02013;<lpage>830</lpage>. <pub-id pub-id-type="doi">10.1158/1535-7163.MCT-16-0444</pub-id>.<pub-id pub-id-type="pmid">28138029</pub-id>
</mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="journal" id="cit21"><name><surname>Parker</surname><given-names>N.</given-names></name>; <name><surname>Turk</surname><given-names>M. J.</given-names></name>; <name><surname>Westrick</surname><given-names>E.</given-names></name>; <name><surname>Lewis</surname><given-names>J. D.</given-names></name>; <name><surname>Low</surname><given-names>P. S.</given-names></name>; <name><surname>Leamon</surname><given-names>C. P.</given-names></name>
<article-title>Folate receptor expression in carcinomas
and normal
tissues determined by a quantitative radioligand binding assay</article-title>. <source>Analytical biochemistry</source>
<year>2005</year>, <volume>338</volume>, <fpage>284</fpage>&#x02013;<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1016/j.ab.2004.12.026</pub-id>.<pub-id pub-id-type="pmid">15745749</pub-id>
</mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="journal" id="cit22"><name><surname>Chattopadhyay</surname><given-names>S.</given-names></name>; <name><surname>Moran</surname><given-names>R. G.</given-names></name>; <name><surname>Goldman</surname><given-names>I. D.</given-names></name>
<article-title>Pemetrexed: biochemical
and cellular
pharmacology, mechanisms, and clinical applications</article-title>. <source>Mol. Cancer Ther</source>
<year>2007</year>, <volume>6</volume>, <fpage>404</fpage>&#x02013;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1158/1535-7163.MCT-06-0343</pub-id>.<pub-id pub-id-type="pmid">17308042</pub-id>
</mixed-citation></ref><ref id="ref23"><mixed-citation publication-type="journal" id="cit23"><name><surname>Wang</surname><given-names>Y.</given-names></name>; <name><surname>Mitchell-Ryan</surname><given-names>S.</given-names></name>; <name><surname>Raghavan</surname><given-names>S.</given-names></name>; <name><surname>George</surname><given-names>C.</given-names></name>; <name><surname>Orr</surname><given-names>S.</given-names></name>; <name><surname>Hou</surname><given-names>Z.</given-names></name>; <name><surname>Matherly</surname><given-names>L. H.</given-names></name>; <name><surname>Gangjee</surname><given-names>A.</given-names></name>
<article-title>Novel 5-substituted
pyrrolo[2,3-d]pyrimidines
as dual inhibitors of glycinamide ribonucleotide formyltransferase
and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase
and as potential antitumor agents</article-title>. <source>J. Med. Chem.</source>
<year>2015</year>, <volume>58</volume>, <fpage>1479</fpage>&#x02013;<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1021/jm501787c</pub-id>.<pub-id pub-id-type="pmid">25602637</pub-id>
</mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="journal" id="cit24"><name><surname>Mitchell-Ryan</surname><given-names>S.</given-names></name>; <name><surname>Wang</surname><given-names>Y.</given-names></name>; <name><surname>Raghavan</surname><given-names>S.</given-names></name>; <name><surname>Ravindra</surname><given-names>M. P.</given-names></name>; <name><surname>Hales</surname><given-names>E.</given-names></name>; <name><surname>Orr</surname><given-names>S.</given-names></name>; <name><surname>Cherian</surname><given-names>C.</given-names></name>; <name><surname>Hou</surname><given-names>Z.</given-names></name>; <name><surname>Matherly</surname><given-names>L. H.</given-names></name>; <name><surname>Gangjee</surname><given-names>A.</given-names></name>
<article-title>Discovery
of 5-substituted pyrrolo[2,3-d]pyrimidine antifolates as dual acting
inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide
ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis:
implications of inhibiting 5-aminoimidazole-4-carboxamide ribonucleotide
formyltransferase to AMPK activation and anti-tumor activity</article-title>. <source>J. Med. Chem.</source>
<year>2013</year>, <volume>56</volume>, <fpage>10016</fpage>&#x02013;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1021/jm401328u</pub-id>.<pub-id pub-id-type="pmid">24256410</pub-id>
</mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="journal" id="cit25"><name><surname>Deng</surname><given-names>Y.</given-names></name>; <name><surname>Wang</surname><given-names>Y.</given-names></name>; <name><surname>Cherian</surname><given-names>C.</given-names></name>; <name><surname>Hou</surname><given-names>Z.</given-names></name>; <name><surname>Buck</surname><given-names>S. A.</given-names></name>; <name><surname>Matherly</surname><given-names>L. H.</given-names></name>; <name><surname>Gangjee</surname><given-names>A.</given-names></name>
<article-title>Synthesis and discovery of high affinity
folate receptor-specific glycinamide ribonucleotide formyltransferase
inhibitors with antitumor activity</article-title>. <source>J. Med.
Chem.</source>
<year>2008</year>, <volume>51</volume>, <fpage>5052</fpage>&#x02013;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1021/jm8003366</pub-id>.<pub-id pub-id-type="pmid">18680275</pub-id>
</mixed-citation></ref><ref id="ref26"><mixed-citation publication-type="journal" id="cit26"><name><surname>Desmoulin</surname><given-names>S. K.</given-names></name>; <name><surname>Wang</surname><given-names>Y.</given-names></name>; <name><surname>Wu</surname><given-names>J.</given-names></name>; <name><surname>Stout</surname><given-names>M.</given-names></name>; <name><surname>Hou</surname><given-names>Z.</given-names></name>; <name><surname>Fulterer</surname><given-names>A.</given-names></name>; <name><surname>Chang</surname><given-names>M. H.</given-names></name>; <name><surname>Romero</surname><given-names>M. F.</given-names></name>; <name><surname>Cherian</surname><given-names>C.</given-names></name>; <name><surname>Gangjee</surname><given-names>A.</given-names></name>; <name><surname>Matherly</surname><given-names>L. H.</given-names></name>
<article-title>Targeting
the proton-coupled folate
transporter for selective delivery of 6-substituted pyrrolo[2,3-d]pyrimidine
antifolate inhibitors of de novo purine biosynthesis in the chemotherapy
of solid tumors</article-title>. <source>Mol. Pharmacol.</source>
<year>2010</year>, <volume>78</volume>, <fpage>577</fpage>&#x02013;<lpage>87</lpage>. <pub-id pub-id-type="doi">10.1124/mol.110.065896</pub-id>.<pub-id pub-id-type="pmid">20601456</pub-id>
</mixed-citation></ref><ref id="ref27"><mixed-citation publication-type="journal" id="cit27"><name><surname>Kugel
Desmoulin</surname><given-names>S.</given-names></name>; <name><surname>Wang</surname><given-names>L.</given-names></name>; <name><surname>Hales</surname><given-names>E.</given-names></name>; <name><surname>Polin</surname><given-names>L.</given-names></name>; <name><surname>White</surname><given-names>K.</given-names></name>; <name><surname>Kushner</surname><given-names>J.</given-names></name>; <name><surname>Stout</surname><given-names>M.</given-names></name>; <name><surname>Hou</surname><given-names>Z.</given-names></name>; <name><surname>Cherian</surname><given-names>C.</given-names></name>; <name><surname>Gangjee</surname><given-names>A.</given-names></name>; <name><surname>Matherly</surname><given-names>L. H.</given-names></name>
<article-title>Therapeutic targeting
of a novel 6-substituted pyrrolo [2,3-d]pyrimidine thienoyl antifolate
to human solid tumors based on selective uptake by the proton-coupled
folate transporter</article-title>. <source>Mol. Pharmacol.</source>
<year>2011</year>, <volume>80</volume>, <fpage>1096</fpage>&#x02013;<lpage>107</lpage>. <pub-id pub-id-type="doi">10.1124/mol.111.073833</pub-id>.<pub-id pub-id-type="pmid">21940787</pub-id>
</mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="journal" id="cit28"><name><surname>Ravindra</surname><given-names>M.</given-names></name>; <name><surname>Wilson</surname><given-names>M. R.</given-names></name>; <name><surname>Tong</surname><given-names>N.</given-names></name>; <name><surname>O&#x02019;Connor</surname><given-names>C.</given-names></name>; <name><surname>Karim</surname><given-names>M.</given-names></name>; <name><surname>Polin</surname><given-names>L.</given-names></name>; <name><surname>Wallace-Povirk</surname><given-names>A.</given-names></name>; <name><surname>White</surname><given-names>K.</given-names></name>; <name><surname>Kushner</surname><given-names>J.</given-names></name>; <name><surname>Hou</surname><given-names>Z.</given-names></name>; <name><surname>Matherly</surname><given-names>L. H.</given-names></name>; <name><surname>Gangjee</surname><given-names>A.</given-names></name>
<article-title>Fluorine-Substituted Pyrrolo[2,3- d]Pyrimidine Analogues
with Tumor Targeting via Cellular Uptake by Folate Receptor alpha
and the Proton-Coupled Folate Transporter and Inhibition of de Novo
Purine Nucleotide Biosynthesis</article-title>. <source>J. Med. Chem.</source>
<year>2018</year>, <volume>61</volume>, <fpage>4228</fpage>&#x02013;<lpage>4248</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.8b00408</pub-id>.<pub-id pub-id-type="pmid">29701475</pub-id>
</mixed-citation></ref><ref id="ref29"><mixed-citation publication-type="journal" id="cit29"><name><surname>Wang</surname><given-names>L.</given-names></name>; <name><surname>Cherian</surname><given-names>C.</given-names></name>; <name><surname>Kugel Desmoulin</surname><given-names>S.</given-names></name>; <name><surname>Polin</surname><given-names>L.</given-names></name>; <name><surname>Deng</surname><given-names>Y.</given-names></name>; <name><surname>Wu</surname><given-names>J.</given-names></name>; <name><surname>Hou</surname><given-names>Z.</given-names></name>; <name><surname>White</surname><given-names>K.</given-names></name>; <name><surname>Kushner</surname><given-names>J.</given-names></name>; <name><surname>Matherly</surname><given-names>L. H.</given-names></name>; <name><surname>Gangjee</surname><given-names>A.</given-names></name>
<article-title>Synthesis
and antitumor activity of a novel series
of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors
of purine biosynthesis with selectivity for high affinity folate receptors
and the proton-coupled folate transporter over the reduced folate
carrier for cellular entry</article-title>. <source>J. Med. Chem.</source>
<year>2010</year>, <volume>53</volume>, <fpage>1306</fpage>&#x02013;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1021/jm9015729</pub-id>.<pub-id pub-id-type="pmid">20085328</pub-id>
</mixed-citation></ref><ref id="ref30"><mixed-citation publication-type="journal" id="cit30"><name><surname>Wang</surname><given-names>L.</given-names></name>; <name><surname>Desmoulin</surname><given-names>S. K.</given-names></name>; <name><surname>Cherian</surname><given-names>C.</given-names></name>; <name><surname>Polin</surname><given-names>L.</given-names></name>; <name><surname>White</surname><given-names>K.</given-names></name>; <name><surname>Kushner</surname><given-names>J.</given-names></name>; <name><surname>Fulterer</surname><given-names>A.</given-names></name>; <name><surname>Chang</surname><given-names>M.-H.</given-names></name>; <name><surname>Mitchell-Ryan</surname><given-names>S.</given-names></name>; <name><surname>Stout</surname><given-names>M.</given-names></name>; <name><surname>Romero</surname><given-names>M. F.</given-names></name>; <name><surname>Hou</surname><given-names>Z.</given-names></name>; <name><surname>Matherly</surname><given-names>L. H.</given-names></name>; <name><surname>Gangjee</surname><given-names>A.</given-names></name>
<article-title>Synthesis, biological, and antitumor activity of a
highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate
inhibitor with proton-coupled folate transporter and folate receptor
selectivity over the reduced folate carrier that inhibits beta-glycinamide
ribonucleotide formyltransferase</article-title>. <source>J. Med. Chem.</source>
<year>2011</year>, <volume>54</volume>, <fpage>7150</fpage>&#x02013;<lpage>7164</lpage>. <pub-id pub-id-type="doi">10.1021/jm200739e</pub-id>.<pub-id pub-id-type="pmid">21879757</pub-id>
</mixed-citation></ref><ref id="ref31"><mixed-citation publication-type="journal" id="cit31"><name><surname>Wang</surname><given-names>L.</given-names></name>; <name><surname>Wallace</surname><given-names>A.</given-names></name>; <name><surname>Raghavan</surname><given-names>S.</given-names></name>; <name><surname>Deis</surname><given-names>S. M.</given-names></name>; <name><surname>Wilson</surname><given-names>M. R.</given-names></name>; <name><surname>Yang</surname><given-names>S.</given-names></name>; <name><surname>Polin</surname><given-names>L.</given-names></name>; <name><surname>White</surname><given-names>K.</given-names></name>; <name><surname>Kushner</surname><given-names>J.</given-names></name>; <name><surname>Orr</surname><given-names>S.</given-names></name>; <name><surname>George</surname><given-names>C.</given-names></name>; <name><surname>O&#x02019;Connor</surname><given-names>C.</given-names></name>; <name><surname>Hou</surname><given-names>Z.</given-names></name>; <name><surname>Mitchell-Ryan</surname><given-names>S.</given-names></name>; <name><surname>Dann</surname><given-names>C. E.</given-names><suffix>3rd</suffix></name>; <name><surname>Matherly</surname><given-names>L. H.</given-names></name>; <name><surname>Gangjee</surname><given-names>A.</given-names></name>
<article-title>6-Substituted
Pyrrolo[2,3-d]pyrimidine Thienoyl Regioisomers as Targeted Antifolates
for Folate Receptor alpha and the Proton-Coupled Folate Transporter
in Human Tumors</article-title>. <source>J. Med. Chem.</source>
<year>2015</year>, <volume>58</volume>, <fpage>6938</fpage>&#x02013;<lpage>59</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.5b00801</pub-id>.<pub-id pub-id-type="pmid">26317331</pub-id>
</mixed-citation></ref><ref id="ref32"><mixed-citation publication-type="journal" id="cit32"><name><surname>C
Taylor</surname><given-names>E.</given-names></name>; <name><surname>Hu</surname><given-names>B.</given-names></name>
<article-title>A Fischer-indole approach to pyrrolo[2,3-<italic>d</italic>]pyrimidines</article-title>. <source>Heterocycles</source>
<year>1996</year>, <volume>43</volume>, <fpage>323</fpage>&#x02013;<lpage>338</lpage>. <pub-id pub-id-type="doi">10.3987/COM-95-7260</pub-id>.</mixed-citation></ref><ref id="ref33"><mixed-citation publication-type="patent" id="cit33"><person-group person-group-type="allauthors"><name><surname>Taylor</surname><given-names>E. C. K.</given-names></name>; <name><surname>D</surname><given-names>G.</given-names></name>; <name><surname>Shih</surname><given-names>C.</given-names></name>; <name><surname>Grindey</surname><given-names>G. B.</given-names></name></person-group><article-title>N-(pyrrolo[2,3-d]pyrimidin-3-ylacyl)-glutamic
acid derivatives</article-title>. <patent>EP0432677A1</patent>, June 19, <year>1991</year>.</mixed-citation></ref><ref id="ref34"><mixed-citation publication-type="journal" id="cit34"><name><surname>Parker</surname><given-names>J. L.</given-names></name>; <name><surname>Deme</surname><given-names>J. C.</given-names></name>; <name><surname>Kuteyi</surname><given-names>G.</given-names></name>; <name><surname>Wu</surname><given-names>Z.</given-names></name>; <name><surname>Huo</surname><given-names>J.</given-names></name>; <name><surname>Goldman</surname><given-names>I. D.</given-names></name>; <name><surname>Owens</surname><given-names>R. J.</given-names></name>; <name><surname>Biggin</surname><given-names>P. C.</given-names></name>; <name><surname>Lea</surname><given-names>S. M.</given-names></name>; <name><surname>Newstead</surname><given-names>S.</given-names></name>
<article-title>Structural basis of antifolate recognition
and transport
by PCFT</article-title>. <source>Nature</source>
<year>2021</year>, <volume>595</volume>, <fpage>130</fpage>&#x02013;<lpage>134</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-021-03579-z</pub-id>.<pub-id pub-id-type="pmid">34040256</pub-id>
</mixed-citation></ref><ref id="ref35"><mixed-citation publication-type="journal" id="cit35"><name><surname>Golani</surname><given-names>L. K.</given-names></name>; <name><surname>Wallace-Povirk</surname><given-names>A.</given-names></name>; <name><surname>Deis</surname><given-names>S. M.</given-names></name>; <name><surname>Wong</surname><given-names>J.</given-names></name>; <name><surname>Ke</surname><given-names>J.</given-names></name>; <name><surname>Gu</surname><given-names>X.</given-names></name>; <name><surname>Raghavan</surname><given-names>S.</given-names></name>; <name><surname>Wilson</surname><given-names>M. R.</given-names></name>; <name><surname>Li</surname><given-names>X.</given-names></name>; <name><surname>Polin</surname><given-names>L.</given-names></name>; <name><surname>de Waal</surname><given-names>P. W.</given-names></name>; <name><surname>White</surname><given-names>K.</given-names></name>; <name><surname>Kushner</surname><given-names>J.</given-names></name>; <name><surname>O&#x02019;Connor</surname><given-names>C.</given-names></name>; <name><surname>Hou</surname><given-names>Z.</given-names></name>; <name><surname>Xu</surname><given-names>H. E.</given-names></name>; <name><surname>Melcher</surname><given-names>K.</given-names></name>; <name><surname>Dann</surname><given-names>C. E.</given-names><suffix>3rd</suffix></name>; <name><surname>Matherly</surname><given-names>L. H.</given-names></name>; <name><surname>Gangjee</surname><given-names>A.</given-names></name>
<article-title>Tumor Targeting with Novel 6-Substituted
Pyrrolo [2,3-d] Pyrimidine Antifolates with Heteroatom Bridge Substitutions
via Cellular Uptake by Folate Receptor alpha and the Proton-Coupled
Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis</article-title>. <source>J. Med. Chem.</source>
<year>2016</year>, <volume>59</volume>, <fpage>7856</fpage>&#x02013;<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.6b00594</pub-id>.<pub-id pub-id-type="pmid">27458733</pub-id>
</mixed-citation></ref><ref id="ref36"><mixed-citation publication-type="journal" id="cit36"><name><surname>Wibowo</surname><given-names>A. S.</given-names></name>; <name><surname>Singh</surname><given-names>M.</given-names></name>; <name><surname>Reeder</surname><given-names>K. M.</given-names></name>; <name><surname>Carter</surname><given-names>J. J.</given-names></name>; <name><surname>Kovach</surname><given-names>A. R.</given-names></name>; <name><surname>Meng</surname><given-names>W.</given-names></name>; <name><surname>Ratnam</surname><given-names>M.</given-names></name>; <name><surname>Zhang</surname><given-names>F.</given-names></name>; <name><surname>Dann</surname><given-names>C. E.</given-names><suffix>3rd</suffix></name>
<article-title>Structures of human folate receptors
reveal biological
trafficking states and diversity in folate and antifolate recognition</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<year>2013</year>, <volume>110</volume>, <fpage>15180</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1308827110</pub-id>.<pub-id pub-id-type="pmid">23934049</pub-id>
</mixed-citation></ref><ref id="ref37"><mixed-citation publication-type="journal" id="cit37"><name><surname>Zhang</surname><given-names>Q.</given-names></name>; <name><surname>Zhang</surname><given-names>X.</given-names></name>; <name><surname>Zhu</surname><given-names>Y.</given-names></name>; <name><surname>Sun</surname><given-names>P.</given-names></name>; <name><surname>Zhang</surname><given-names>L.</given-names></name>; <name><surname>Ma</surname><given-names>J.</given-names></name>; <name><surname>Zhang</surname><given-names>Y.</given-names></name>; <name><surname>Zeng</surname><given-names>L.</given-names></name>; <name><surname>Nie</surname><given-names>X.</given-names></name>; <name><surname>Gao</surname><given-names>Y.</given-names></name>; <name><surname>Li</surname><given-names>Z.</given-names></name>; <name><surname>Liu</surname><given-names>S.</given-names></name>; <name><surname>Lou</surname><given-names>J.</given-names></name>; <name><surname>Gao</surname><given-names>A.</given-names></name>; <name><surname>Zhang</surname><given-names>L.</given-names></name>; <name><surname>Gao</surname><given-names>P.</given-names></name>
<article-title>Recognition of cyclic dinucleotides
and folates by human SLC19A1</article-title>. <source>Nature</source>
<year>2022</year>, <volume>612</volume>, <fpage>170</fpage>&#x02013;<lpage>176</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-022-05452-z</pub-id>.<pub-id pub-id-type="pmid">36265513</pub-id>
</mixed-citation></ref><ref id="ref38"><mixed-citation publication-type="computer-program" id="cit38"><source>Schr&#x000f6;dinger</source><italic>,</italic> Release 2023&#x02013;1; <publisher-name>MacroModel,
S., LLC</publisher-name>: <publisher-loc>New York, NY</publisher-loc>, <year>2021</year>.</mixed-citation></ref><ref id="ref39"><mixed-citation publication-type="journal" id="cit39"><name><surname>Flintoff</surname><given-names>W.
F.</given-names></name>; <name><surname>Davidson</surname><given-names>S. V.</given-names></name>; <name><surname>Siminovitch</surname><given-names>L.</given-names></name>
<article-title>Isolation and partial characterization
of three methotrexate-resistant phenotypes from Chinese hamster ovary
cells</article-title>. <source>Somatic Cell Genet.</source>
<year>1976</year>, <volume>2</volume>, <fpage>245</fpage>&#x02013;<lpage>261</lpage>. <pub-id pub-id-type="doi">10.1007/BF01538963</pub-id>.<pub-id pub-id-type="pmid">1028172</pub-id>
</mixed-citation></ref><ref id="ref40"><mixed-citation publication-type="journal" id="cit40"><name><surname>Flintoff</surname><given-names>W. F.</given-names></name>; <name><surname>Nagainis</surname><given-names>C. R.</given-names></name>
<article-title>Transport of methotrexate
in Chinese hamster ovary
cells: a mutant defective in methotrexate uptake and cell binding</article-title>. <source>Arch. Biochem. Biophys.</source>
<year>1983</year>, <volume>223</volume>, <fpage>433</fpage>&#x02013;<lpage>440</lpage>. <pub-id pub-id-type="doi">10.1016/0003-9861(83)90607-0</pub-id>.<pub-id pub-id-type="pmid">6859869</pub-id>
</mixed-citation></ref><ref id="ref41"><mixed-citation publication-type="journal" id="cit41"><name><surname>Wong</surname><given-names>S. C.</given-names></name>; <name><surname>Proefke</surname><given-names>S. A.</given-names></name>; <name><surname>Bhushan</surname><given-names>A.</given-names></name>; <name><surname>Matherly</surname><given-names>L. H.</given-names></name>
<article-title>Isolation
of human
cDNAs that restore methotrexate sensitivity and reduced folate carrier
activity in methotrexate transport-defective Chinese hamster ovary
cells</article-title>. <source>J. Biol. Chem.</source>
<year>1995</year>, <volume>270</volume>, <fpage>17468</fpage>&#x02013;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.270.29.17468</pub-id>.<pub-id pub-id-type="pmid">7615551</pub-id>
</mixed-citation></ref><ref id="ref42"><mixed-citation publication-type="journal" id="cit42"><name><surname>Deng</surname><given-names>Y.</given-names></name>; <name><surname>Zhou</surname><given-names>X.</given-names></name>; <name><surname>Kugel Desmoulin</surname><given-names>S.</given-names></name>; <name><surname>Wu</surname><given-names>J.</given-names></name>; <name><surname>Cherian</surname><given-names>C.</given-names></name>; <name><surname>Hou</surname><given-names>Z.</given-names></name>; <name><surname>Matherly</surname><given-names>L. H.</given-names></name>; <name><surname>Gangjee</surname><given-names>A.</given-names></name>
<article-title>Synthesis
and biological activity
of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate
inhibitors of purine biosynthesis with selectivity for high affinity
folate receptors over the reduced folate carrier and proton-coupled
folate transporter for cellular entry</article-title>. <source>J. Med.
Chem.</source>
<year>2009</year>, <volume>52</volume>, <fpage>2940</fpage>&#x02013;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1021/jm8011323</pub-id>.<pub-id pub-id-type="pmid">19371039</pub-id>
</mixed-citation></ref><ref id="ref43"><mixed-citation publication-type="journal" id="cit43"><name><surname>Karve</surname><given-names>T. M.</given-names></name>; <name><surname>Preet</surname><given-names>A.</given-names></name>; <name><surname>Sneed</surname><given-names>R.</given-names></name>; <name><surname>Salamanca</surname><given-names>C.</given-names></name>; <name><surname>Li</surname><given-names>X.</given-names></name>; <name><surname>Xu</surname><given-names>J.</given-names></name>; <name><surname>Kumar</surname><given-names>D.</given-names></name>; <name><surname>Rosen</surname><given-names>E. M.</given-names></name>; <name><surname>Saha</surname><given-names>T.</given-names></name>
<article-title>BRCA1 regulates
follistatin function in ovarian cancer and human ovarian surface epithelial
cells</article-title>. <source>PLoS One</source>
<year>2012</year>, <volume>7</volume>, <elocation-id>e37697</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0037697</pub-id>.<pub-id pub-id-type="pmid">22685544</pub-id>
</mixed-citation></ref><ref id="ref44"><mixed-citation publication-type="journal" id="cit44"><name><surname>Wallace-Povirk</surname><given-names>A.</given-names></name>; <name><surname>Tong</surname><given-names>N.</given-names></name>; <name><surname>Wong-Roushar</surname><given-names>J.</given-names></name>; <name><surname>O&#x02019;Connor</surname><given-names>C.</given-names></name>; <name><surname>Zhou</surname><given-names>X.</given-names></name>; <name><surname>Hou</surname><given-names>Z.</given-names></name>; <name><surname>Bao</surname><given-names>X.</given-names></name>; <name><surname>Garcia</surname><given-names>G. E.</given-names></name>; <name><surname>Li</surname><given-names>J.</given-names></name>; <name><surname>Kim</surname><given-names>S.</given-names></name>; <name><surname>Dann</surname><given-names>C. E.</given-names><suffix>3rd</suffix></name>; <name><surname>Matherly</surname><given-names>L. H.</given-names></name>; <name><surname>Gangjee</surname><given-names>A.</given-names></name>
<article-title>Discovery of 6-substituted
thieno[2,3-d]pyrimidine
analogs as dual inhibitors of glycinamide ribonucleotide formyltransferase
and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase
in de novo purine nucleotide biosynthesis in folate receptor expressing
human tumors</article-title>. <source>Bioorg. Med. Chem.</source>
<year>2021</year>, <volume>37</volume>, <fpage>116093</fpage><pub-id pub-id-type="doi">10.1016/j.bmc.2021.116093</pub-id>.<pub-id pub-id-type="pmid">33773393</pub-id>
</mixed-citation></ref><ref id="ref45"><mixed-citation publication-type="journal" id="cit45"><name><surname>Dekhne</surname><given-names>A. S.</given-names></name>; <name><surname>Shah</surname><given-names>K.</given-names></name>; <name><surname>Ducker</surname><given-names>G. S.</given-names></name>; <name><surname>Katinas</surname><given-names>J. M.</given-names></name>; <name><surname>Wong-Roushar</surname><given-names>J.</given-names></name>; <name><surname>Nayeen</surname><given-names>M. J.</given-names></name>; <name><surname>Doshi</surname><given-names>A.</given-names></name>; <name><surname>Ning</surname><given-names>C.</given-names></name>; <name><surname>Bao</surname><given-names>X.</given-names></name>; <name><surname>Fruhauf</surname><given-names>J.</given-names></name>; <name><surname>Liu</surname><given-names>J.</given-names></name>; <name><surname>Wallace-Povirk</surname><given-names>A.</given-names></name>; <name><surname>O&#x02019;Connor</surname><given-names>C.</given-names></name>; <name><surname>Dzinic</surname><given-names>S. H.</given-names></name>; <name><surname>White</surname><given-names>K.</given-names></name>; <name><surname>Kushner</surname><given-names>J.</given-names></name>; <name><surname>Kim</surname><given-names>S.</given-names></name>; <name><surname>Huttemann</surname><given-names>M.</given-names></name>; <name><surname>Polin</surname><given-names>L.</given-names></name>; <name><surname>Rabinowitz</surname><given-names>J. D.</given-names></name>; <name><surname>Li</surname><given-names>J.</given-names></name>; <name><surname>Hou</surname><given-names>Z.</given-names></name>; <name><surname>Dann</surname><given-names>C. E.</given-names><suffix>3rd</suffix></name>; <name><surname>Gangjee</surname><given-names>A.</given-names></name>; <name><surname>Matherly</surname><given-names>L. H.</given-names></name>
<article-title>Novel Pyrrolo[3,2-d]pyrimidine
Compounds Target Mitochondrial
and Cytosolic One-carbon Metabolism with Broad-spectrum Antitumor
Efficacy</article-title>. <source>Mol. Cancer Ther</source>
<year>2019</year>, <volume>18</volume>, <fpage>1787</fpage>&#x02013;<lpage>1799</lpage>. <pub-id pub-id-type="doi">10.1158/1535-7163.MCT-19-0037</pub-id>.<pub-id pub-id-type="pmid">31289137</pub-id>
</mixed-citation></ref><ref id="ref46"><mixed-citation publication-type="journal" id="cit46"><name><surname>Benard</surname><given-names>J.</given-names></name>; <name><surname>Da Silva</surname><given-names>J.</given-names></name>; <name><surname>De Blois</surname><given-names>M. C.</given-names></name>; <name><surname>Boyer</surname><given-names>P.</given-names></name>; <name><surname>Duvillard</surname><given-names>P.</given-names></name>; <name><surname>Chiric</surname><given-names>E.</given-names></name>; <name><surname>Riou</surname><given-names>G.</given-names></name>
<article-title>Characterization
of a human ovarian
adenocarcinoma line, IGROV1, in tissue culture and in nude mice</article-title>. <source>Cancer Res.</source>
<year>1985</year>, <volume>45</volume>, <fpage>4970</fpage>&#x02013;<lpage>4979</lpage>.<pub-id pub-id-type="pmid">3861241</pub-id>
</mixed-citation></ref><ref id="ref47"><mixed-citation publication-type="journal" id="cit47"><name><surname>Barreiro</surname><given-names>E. J.</given-names></name>; <name><surname>K&#x000fc;mmerle</surname><given-names>A. E.</given-names></name>; <name><surname>Fraga</surname><given-names>C. A. M.</given-names></name>
<article-title>The methylation effect in medicinal
chemistry</article-title>. <source>Chem. Rev.</source>
<year>2011</year>, <volume>111</volume>, <fpage>5215</fpage>&#x02013;<lpage>5246</lpage>. <pub-id pub-id-type="doi">10.1021/cr200060g</pub-id>.<pub-id pub-id-type="pmid">21631125</pub-id>
</mixed-citation></ref><ref id="ref48"><mixed-citation publication-type="journal" id="cit48"><name><surname>Bissantz</surname><given-names>C.</given-names></name>; <name><surname>Kuhn</surname><given-names>B.</given-names></name>; <name><surname>Stahl</surname><given-names>M.</given-names></name>
<article-title>A medicinal
chemist&#x02019;s guide
to molecular interactions</article-title>. <source>J. Med. Chem.</source>
<year>2010</year>, <volume>53</volume>, <fpage>5061</fpage>&#x02013;<lpage>5084</lpage>. <pub-id pub-id-type="doi">10.1021/jm100112j</pub-id>.<pub-id pub-id-type="pmid">20345171</pub-id>
</mixed-citation></ref><ref id="ref49"><mixed-citation publication-type="journal" id="cit49"><name><surname>Leung</surname><given-names>C. S.</given-names></name>; <name><surname>Leung</surname><given-names>S. S. F.</given-names></name>; <name><surname>Tirado-Rives</surname><given-names>J.</given-names></name>; <name><surname>Jorgensen</surname><given-names>W. L.</given-names></name>
<article-title>Methyl
effects on protein-ligand binding</article-title>. <source>J. Med. Chem.</source>
<year>2012</year>, <volume>55</volume>, <fpage>4489</fpage>&#x02013;<lpage>4500</lpage>. <pub-id pub-id-type="doi">10.1021/jm3003697</pub-id>.<pub-id pub-id-type="pmid">22500930</pub-id>
</mixed-citation></ref><ref id="ref50"><mixed-citation publication-type="journal" id="cit50"><name><surname>Schonherr</surname><given-names>H.</given-names></name>; <name><surname>Cernak</surname><given-names>T.</given-names></name>
<article-title>Profound methyl effects
in drug discovery and a call
for new C&#x025a1;H methylation reactions</article-title>. <source>Angew.
Chem., Int. Ed.</source>
<year>2013</year>, <volume>52</volume>, <fpage>12256</fpage>&#x02013;<lpage>12267</lpage>. <pub-id pub-id-type="doi">10.1002/anie.201303207</pub-id>.</mixed-citation></ref></ref-list></back></article>
